Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Nedisertib in Advanced Malignant Solid Neoplasm: NCT05868174 Clinical Landscape Report 2026
16 October 2026
NCT05868174 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Evorpacept in Colonic Cancer: NCT05868226 Clinical Landscape Report 2026
16 October 2026
NCT05868226 clinical landscape for Colonic Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TY-2699a in Locally Advanced Malignant Solid Neoplasm: NCT05866692 Clinical Landscape Report 2026
16 October 2026
NCT05866692 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Datopotamab Deruxtecan in Triple Negative Breast Cancer: NCT05866432 Clinical Landscape Report 2026
16 October 2026
NCT05866432 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Triple Negative Breast Cancer: NCT05872412 Clinical Landscape Report 2026
16 October 2026
NCT05872412 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
WP-1066 in Glioblastoma, IDH-Wildtype: NCT05879250 Clinical Landscape Report 2026
16 October 2026
NCT05879250 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Diffuse Large B-Cell Lymphoma: NCT05887726 Clinical Landscape Report 2026
16 October 2026
NCT05887726 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: NCT05890352 Clinical Landscape Report 2026
16 October 2026
NCT05890352 clinical landscape for High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: endpoints, sponsor, phase, geography, readouts, a…
9 min read
Tislelizumab in Fumarate Hydratase-Deficient Renal Cell Carcinoma: NCT05877820 Clinical Landscape Report 2026
16 October 2026
NCT05877820 clinical landscape for Fumarate Hydratase-Deficient Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Leucovorin Calcium in Ovarian Cancer: NCT05891171 Clinical Landscape Report 2026
16 October 2026
NCT05891171 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT05879367 Clinical Landscape Report 2026
16 October 2026
NCT05879367 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Recurrent Glioblastoma: NCT05879120 Clinical Landscape Report 2026
16 October 2026
NCT05879120 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.